FDA Staff Mixed on Blood Thinner Brilinta

WASHINGTON, July 26 (Reuters) - U.S. reviewers gave mixed views on AstraZeneca Plc's (AZN.L) experimental blood thinner but the company's shares rose on investor optimism that an advisory panel will back the potential blockbuster drug.